Navigation Links
Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants
Date:1/27/2010

LOS ANGELES, Jan. 27 /PRNewswire/ -- Los Angeles-based plastic surgeon, Dr. Jay Calvert, posted more information about the IDEAL breast implants on his blog. He discussed the frequently asked questions about this new product and discussed when it would be available to the public for a clinical trial.

Board-certified Dr. Jay Calvert was chosen as one of the investigators of the new IDEAL breast implants. These implants are known to have the same result as that of silicone gel but are much safer. The clinical trial has begun accepting patients who are willing to undergo the procedure and commit to follow up check ups for the next 10 years.

More and more women are turning to cosmetic surgeries such as breast augmentation and rhinoplasty in order to enhance their looks. The increase in the demand for these types of operations have paved the way for new procedures and tools to be developed in order to ensure the safety of the patients. Among these new developments is the IDEAL breast implant.

"This [IDEAL breast implant] is the first improvement in the basic design of the saline-filled breast implant since it was introduced over 30 years ago,'' explained Dr. Calvert when asked about the new product. The IDEAL breast implant is saline-filled and structurally lowered in order to fit better to the chest wall. It was also designed so that it doesn't wrinkle and would feel and look natural.

The clinical trial for this new product is currently ongoing and patients are being selected to undergo the treatment. The trial program specifies that the patient must pay for the breast augmentation; however, if they are able to complete the 10-year clinical trial, then they will be able to receive some financial benefit. Dr. Calvert, MD, FACS, who is one of the surgeons performing this clinical trial, said that it is like an insurance policy; the company will put part of the patient's payment in her trust fund, and after 10 years, the trust fund is expected to grow to about 10000 U.S. Dollars. Dr. Calvert added that "women who entered the study will then have the comfort of knowing that there's money for them at the end of the study, if they do all their follow-ups and complete the study properly." Even though Dr. Calvert is optimistic about this new breast augmentation technique, he still adds that, "if problems come up and we need to draw upon that money and stop the study, then there's money there to do that."

Certified by the American Board of Plastic Surgery, Dr. Calvert also performs other cosmetic surgeries including breast augmentation, post-bariatric surgery, face-lift and rhinoplasty among others. He is based in Los Angeles, California and sees new patients at his two offices in Beverly Hills and Newport Beach.

Press Release Contact Information:

JayCalvertMD.com

1-888-895-5605

dr.calvert09@gmail.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.

SOURCE Dr. Jay Calvert MD - Los Angeles Plastic Surgeon

RELATED LINKS
http://www.JayCalvertMD.com

'/>"/>

SOURCE Dr. Jay Calvert MD - Los Angeles Plastic Surgeon
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Catholic Health Initiatives Makes $10 Million Investment in Calvert Foundations Community Investment Notes
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: